역류성 식도염(위식도 역류증) : 시장 전망

This report provides a data-driven overview of the current and future competitive landscape in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics.

In 2025, there were 308.98 million 12- month total diagnosed prevalent cases of GERD in the 16 countries covered in GlobalData's epidemiology forecast.

The management of GERD typically includes a mix of lifestyle adjustments, medication-based treatments, and, in certain cases, surgical or procedural options. Key therapy classes showing this effect include PPIs, histamine H2 receptor (HRH2) antagonists, and dopamine receptor antagonists. P-CABs, a novel class of highly effective acid-suppressing drugs, are now emerging as a preferred option in several major Asian markets.

The GERD pipeline holds 62 molecules, with five assets in the pre-registration stage, eight assets in Phase III development, and four assets in Phase II development.

Over the past decade, 1,281 clinical trials have been conducted in GERD. The year with the most studies initiated was 2024, with 225 trials, followed by 2021 with 162 trials.

Over the past decade, acquisitions accounted for the largest share of deals in North America (50%), Europe (65%), APAC (57.9%), and Africa (57.1%). In South America, acquisitions, asset transactions, and licensing agreements contributed equally (33.3% each).

The consensus from PMR is that the treatment landscape is converging globally on PPIs + P-CABs for pharmacological management, with meaningful market differences in P-CAB access. PPIs are still considered the first-line therapy, before escalating to P-CABs or surgical/endoscopic options.

Scope

GlobalData's Diabetic Retinopathy: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule type
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Reflux Esophagitis (Gastroesophageal Reflux Disease)Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview of Drugs by Approval and Drug Type
• 4.3 Overview of Drugs by Molecule Type
• 4.4 Overview of Drugs by MOA
• 4.5 Product Profile and Sales Forecast

5 Unmet need

6 Pricing and Reimbursement Assessment

7 Pipeline Drugs Assessment

• 7.1 Pipeline Drugs
• 7.2 Overview by Development Stage
• 7.3 Overview by Mechanism of Action
• 7.4 Overview by Molecule Type
• 7.5 Product Profile and Sales Forecast
• 7.6 Drug-specific PTSR and LoA
• 7.7 Indication-specific and Therapy Area-specific PTSR and LoA

8 Clinical Trials Assessment

• 8.1 Historical Overview
• 8.2 Overview by Phase
• 8.3 Overview by Status
• 8.4 Overview by Phase for Ongoing and Planned Trials
• 8.5 Trials with Virtual Components
• 8.6 Top 20 Biomarkers by Trial Phase
• 8.7 Overview of Trials by Geography
• 8.8 Single-Country and Multinational Trials by Region
• 8.9 Top 20 Sponsors with Breakdown by Phase
• 8.10 Top 20 Sponsors with Breakdown by Status
• 8.11 Overview by Endpoint Status
• 8.12 Overview by Race and Ethnicity
• 8.13 Enrollment Data
• 8.14 Top 20 countries for Trial Sites
• 8.15 Top 20 Sites Globally
• 8.16 Feasibility Analysis - Geographic Overview
• 8.17 Feasibility Analysis - Benchmark Models

9 Deals Landscape

• 9.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 9.2 Recent Mergers, Acquisitions, and Strategic Alliances

10 Commercial Assessment

• 10.1 Key Market Players

11 Future Market Catalysts

12 Appendix

• 12.1 Methodology
• 12.2 Methodology - Sales Forecast
• 12.3 Methodology - Pricing and Reimbursement
• 12.4 Methodology - PTSR and LoA Analysis
• 12.5 About the Authors
• 12.6 Contact Us
• 12.7 Disclaimer